A Comprehensive Review of Hepatitis A, B, and C Vaccine Comparisons
DOI:
https://doi.org/10.63142/ijeti.v1i1.243Keywords:
Hepatitis, Vaccine, Effectiveness, Prevention, AntiviralAbstract
Hepatitis is a disease that causes inflammation of the liver due to viral infection or non-infectious factors, such as drug use and metabolic disorders. This disease is divided into hepatitis A, B, and C with hepatitis B and C potentially developing into cirrhosis and liver cancer. This study aims to compare hepatitis A, B, and C vaccines based on virus characteristics, production methods, target recipients, administration methods, mechanisms of action, and effectiveness. The method used is a literature review from scientific databases such as PubMed and Google Scholar. The results show that hepatitis A and B vaccines are widely available with an effectiveness of more than 90%, while hepatitis C does not yet have a vaccine, so its treatment relies on Direct-Acting Antivirals (DAAs) therapy with a success rate of more than 95%. Although the hepatitis B vaccine is effective, challenges remain in global vaccination coverage, especially in developing countries. Public awareness and access to more affordable therapy are important factors in efforts to prevent and control hepatitis.
References
A. T. Novarina., E. Santoso., & I. Indriati. 2018. Sistem Pakar Diagnosis Penyakit Hepatitis Menggunakan Metode Dempster Shafer. Jurnal Pengembangan Teknologi Informasi dan Ilmu Komputer, vol. 2, no. 6, 2252-2258 pp.
D. S. Sitorus., & A. Desiani. 2024. Hepatitis Disease Diagnosis Expert System Using Certainty Factor Method: Hepatitis Disease Diagnosis Expert System Using Certainty Factor Method. Jurnal Mahasiswa Teknik Informatika, vol 3, no. 1, 212-219 pp.
S. S. Nurwananda., & R. Sulaiman. 2022. Aplikasi himpunan fuzzy intuisionistik dalam diagnosa penyakit hepatitis menggunakan extended hausdorff distance. MATHunesa: Jurnal Ilmiah Matematika, vol 10, no. 1, 41-49 pp.
C. Trepo. 2014. A brief history of hepatitis milestones. Liver International, vol. 34, 29-37 ppt.
Centers for Disease Control and Prevention (CDC). 2007. "Recommendations for postexposure prophylaxis for hepatitis A." MMWR Recommendations and Reports.
Centers for Disease Control and Prevention. 2023. Hepatitis A and B vaccines: Recommendations and efficacy. Retrieved from https://www.cdc.gov/hepatitis
World Health Organization. 2023. Hepatitis prevention and treatment strategies.
Pawlotsky, J. M. 2022. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, vol. 162, no. 1, 32-45 pp.
Feld, J. J., & Jacobson, I. M. 2022. Hepatitis C: New developments in antiviral therapy. The New England Journal of Medicine, vol. 387, no. 5, 421-432 pp.
O. Gholizadeh., S. Akbarzadeh., M. H. Ghazanfari., M. Gholami., P. Amini., S. Yekanipour, & V. Poortahmasebi. 2023. Hepatitis A: viral structure, classification, life cycle, clinical symptoms, diagnosis error, and vaccination. Canadian Journal of Infectious Diseases and Medical Microbiology, no. 1, 1-7 pp.
World Health Organization (WHO). (2021). "Hepatitis B."
World Health Organization. (2023). Hepatitis C.
Centers for Disease Control and Prevention. (2023). Hepatitis C questions and answers for the public.
L. Zhang. 2020. Hepatitis A vaccination. Human Vaccines & Immunotherapeutics, vol. 16, no. 7, 1565-1573 pp.
Alter, M. J. 2006. "Epidemiology of hepatitis B and C viruses: a global perspective." Journal of Hepatology, no. 44, 6-9 pp.
Wyles, D. L., & Luetkemeyer, A. F. (2023). Advances in the treatment of hepatitis C virus infection: Clinical implications of direct-acting antivirals. Clinical Infectious Diseases, vol. 76, no. 3, 450-460 pp.
C. Robert & J. Andrew. 2021. Hepatitis A. American Family Physician. Vol. 104, no. 4, 368-374 pp.
J. A. Katz., & S. J. Hwang. 2019. "The role of recombinant DNA technology in the development of hepatitis B vaccines." Human Vaccines & Immunotherapeutics, vol. 15, no. 5, 1123-1130 pp.
American Association for the Study of Liver Diseases. (2023). HCV guidance: Recommendations for testing, managing, and treating hepatitis C.
L. D. Lestari., & R. Raveinal. 2020. Travel vaccine. Human Care Journal, vol. 5, no. 3, 661-670 pp.
B. S. Graham., & N. J. Sullivan. 2018. "Emerging viral diseases: The role of vaccines." Nature Reviews Immunology, vol. 18, no. 5, 309-320 pp.
R. L. Coffman., A. Sher., R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity. Vol. 33, no. 4:492-503 pp.
S. J. Smerdon. 2015. Protein Structure and Function. In Plopper, G., Sharp, D. and Sikorski, E. Lewin’s cell. (3rd ed). Jones & Bartlett Learning, LLC. 169-228 pp.
American Academy of Pediatrics Committee on Infectious Diseases. (2007). Hepatitis A vaccine recommendations. Pediatrics, vol. 120, no. 1, 189-199 pp.
Y. Zhang., et al. 2018. "Efficacy of hepatitis B vaccine in newborns: A systematic review." Vaccine, vol. 36, no. 12, 1645-1652 pp
J. H. Lee., et al. 2020. "Immunogenicity of hepatitis B vaccine in healthcare workers: A cohort study." Journal of Occupational Health, 62(1).
J. J. Feld., & I. M. Jacobson. 2022. Hepatitis C: New developments in antiviral therapy. The New England Journal of Medicine, no. 387, no. 5, 421-432 pp.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yahya Ayasy AlMuhandis, Nadila Suci Nugraha, Rosis Ainin Faqihah (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
How to Cite
